LMR Partners’s Zevra Therapeutics ZVRA Stock Holding History

LMR Partners’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-100,000	Closed	-$834K	–	1673
2024 Q4	$834K	Buy	100,000 +50,000	+100%	+$427K	0.01%	757
2024 Q3	$347K	Buy	+50,000	New	+$339K	﹤0.01%	886
2022 Q4	–	Sell	-10,572	Closed	-$66K	–	1296
2022 Q3	$66K	Hold	10,572	–	–	﹤0.01%	1076
2022 Q2	$47K	Buy	+10,572	New	+$48.2K	﹤0.01%	1166

Other funds holding ZVRA

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

LMR Partners's ZVRA Position: Q1 2025 in Review

LMR Partners sold out of Zevra Therapeutics (ZVRA) in Q1 2025, closing a stake of 100,000 shares — an estimated $834K sold.

LMR Partners first reported a position in ZVRA in Q2 2022 and held it in 4 quarters. The position peaked at $834K in Q4 2024. 110 funds tracked by Wall St. Rank hold ZVRA as of Q1 2025.

LMR Partners reported no remaining Zevra Therapeutics position as of Q1 2025 after selling out during the quarter.
LMR Partners sold 100,000 Zevra Therapeutics shares in Q1 2025, an estimated $834K.
LMR Partners first reported a position in Zevra Therapeutics in Q2 2022 and held it in 4 quarters.
LMR Partners's Zevra Therapeutics position peaked at $834K in Q4 2024.
110 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.